Synovics Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is November - October.

Millions USD. Fiscal year is Nov - Oct.

Fiscal Year	TTM	FY 2008	FY 2007	FY 2006	FY 2005	FY 2004
Period Ending	Jul '09 Jul 31, 2009	Oct '08 Oct 31, 2008	Oct '07 Oct 31, 2007	Oct '06 Oct 31, 2006	Oct '05 Oct 31, 2005	Oct '04 Oct 31, 2004
Revenue	19.09	25.96	23.47	10.52	0.01	0.1
Revenue Growth (YoY)	-18.48%	10.63%	123.14%	128274.00%	-91.71%	208.86%
Cost of Revenue	14.63	16.99	16.84	8.16	0.05	0.02
Gross Profit	4.47	8.97	6.63	2.36	-0.04	0.08
Selling, General & Admin	7.62	10.28	15.6	4.78	0.35	0.87
Research & Development	1.17	1.18	1.29	1.2	1.52	0
Operating Expenses	8.78	11.45	16.89	5.98	1.87	0.87
Operating Income	-4.32	-2.48	-10.26	-3.62	-1.91	-0.79
Interest Expense	-0.71	-4.17	-6.4	-3.91	-0.79	-0
Other Non Operating Income (Expenses)	0	-	0.01	-	0.01	-0
EBT Excluding Unusual Items	-5.02	-6.65	-16.65	-7.53	-2.69	-0.79
Impairment of Goodwill	-0.66	-0.66	-4.01	-	-	-
Gain (Loss) on Sale of Assets	-0.02	-0.02	-0.2	-	-	-
Other Unusual Items	-	3.33	-	-	-	-
Pretax Income	-5.04	-4.01	-20.86	-7.53	-2.69	-0.79
Earnings From Continuing Operations	-5.04	-4.01	-20.86	-7.53	-2.69	-0.79
Earnings From Discontinued Operations	-	-	-	-1.04	-0.22	-0.33
Net Income	-5.04	-4.01	-20.86	-8.57	-2.91	-1.12
Net Income to Common	-5.04	-4.01	-20.86	-8.57	-2.91	-1.12
Shares Outstanding (Basic)	28	24	19	26	20	8
Shares Outstanding (Diluted)	28	24	19	26	20	8
Shares Change (YoY)	84.15%	23.47%	-26.78%	29.61%	156.30%	80.13%
EPS (Basic)	-0.18	-0.17	-1.09	-0.33	-0.14	-0.14
EPS (Diluted)	-0.18	-0.17	-1.09	-0.33	-0.14	-0.14
Free Cash Flow	1.77	3.15	-3.12	-5.61	-2.5	-0.64
Free Cash Flow Per Share	0.06	0.13	-0.16	-0.22	-0.12	-0.08
Gross Margin	23.39%	34.56%	28.25%	22.42%	-	81.50%
Operating Margin	-22.62%	-9.57%	-43.74%	-34.41%	-23334.53%	-796.23%
Profit Margin	-26.42%	-15.43%	-88.88%	-81.50%	-35537.84%	-1138.37%
Free Cash Flow Margin	9.29%	12.15%	-13.29%	-53.38%	-30467.47%	-651.93%
EBITDA	-3.64	-1.87	-9.67	-3.5	-1.88	-0.76
EBITDA Margin	-19.09%	-7.21%	-41.20%	-33.25%	-	-
D&A For EBITDA	0.67	0.61	0.6	0.12	0.03	0.03
EBIT	-4.32	-2.48	-10.26	-3.62	-1.91	-0.79
EBIT Margin	-22.62%	-9.57%	-43.74%	-34.41%	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.